Newsletters

[Resolution Therapeutics] Resolution Therapeutics Limited announced that the final patient has been treated in EMERALD, the Company’s Phase I/II clinical trial evaluating its engineered RMT, RTX001, in patients with end-stage liver disease (ESLD) and a history of decompensated liver cirrhosis.

[Emulate, Inc.] Emulate, Inc. announced it has submitted its FDA Innovative Science and Technology Approaches for New Drugs (ISTAND) full qualification package for its Human Liver-Chip, advancing the company’s efforts to establish Organ-on-a-Chip technology.

[Nature Communications] Researchers showed a nanosystem that generated in-situ radical-conjugated species with predefined targeting capability toward oncogenic proteins, enabling site-specific radical delivery in hepatocellular carcinoma.

[Science] Investigators found platinum agents caused a specific mutational signature in the livers of children that was absent from other exposed normal tissues. They corroborated this observation through cell line and mouse experiments.

[Nature Metabolism] Scientists showed that UBE2N, a ubiquitin-conjugating enzyme that specializes in creating K63, was downregulated by THAP11 in human and mouse hepatocytes with metabolic dysfunction-associated steatohepatitis.

[Science Advances] The authors proposed that compensatory arginine methylation primes metabolic dysfunction–associated steatotic liver disease-associated HCC by modulating m6A-mediated transcriptome and NRF2 regulatory pathways as adaptive defenses against metabolic and oxidative stress.

[Experimental & Molecular Medicine] Researchers used a human embryonic stem cell-derived hepatocyte organoid differentiation model, identifying JMJD3 as a critical regulator of hepatocyte maturation through metabolic–epigenetic coupling.

[Cell Death & Disease] Investigators used hepatocyte-specific RIPK1 knockout mice and demonstrated that loss of RIPK1 markedly aggravates ethanol-induced liver injury, supported by liver specimens from alcoholic liver disease patients.

[International Journal of Biological Macromolecules] Scientists demonstrated that METTL15, an N4-methylcytidine (m4C) RNA methyltransferase, promoted HCC cell proliferation and metastasis both in vitro and in vivo.

[Stem Cell Reports] The authors used the direct reprogramming of fibroblasts into induced hepatocyte-like cells as a model to address why some cells reprogram under identical conditions, while others do not.

[Acta Pharmacologica Sinica] Researchers used cross-omics analysis, in vitro, and in vivo experiments, and identified ATPase Na+/K+ transporting subunit alpha 1 (ATP1A1) as a novel target of YAP/TEA domain transcription factor 4 mechano-responsive transcription factor complex, which promotes tumor cell proliferation.

[Cell Reports Physical Science] Investigators reported a galactose-modified, reactive oxygen species (ROS)-responsive glycopolymer micelle for metabolic dysfunction-associated steatohepatitis management.